Zhejiang CONBA Pharmaceutical Co.,Ltd.

SHSE:600572 Stock Report

Market Cap: CN¥11.9b

Zhejiang CONBA PharmaceuticalLtd Balance Sheet Health

Financial Health criteria checks 6/6

Zhejiang CONBA PharmaceuticalLtd has a total shareholder equity of CN¥6.8B and total debt of CN¥420.8M, which brings its debt-to-equity ratio to 6.2%. Its total assets and total liabilities are CN¥9.7B and CN¥3.0B respectively. Zhejiang CONBA PharmaceuticalLtd's EBIT is CN¥409.8M making its interest coverage ratio -5.5. It has cash and short-term investments of CN¥803.2M.

Key information

6.2%

Debt to equity ratio

CN¥420.77m

Debt

Interest coverage ratio-5.5x
CashCN¥803.16m
EquityCN¥6.75b
Total liabilitiesCN¥2.99b
Total assetsCN¥9.75b

Recent financial health updates

Recent updates

Zhejiang CONBA PharmaceuticalLtd's (SHSE:600572) Problems Go Beyond Weak Profit

Nov 05
Zhejiang CONBA PharmaceuticalLtd's (SHSE:600572) Problems Go Beyond Weak Profit

It's A Story Of Risk Vs Reward With Zhejiang CONBA Pharmaceutical Co.,Ltd. (SHSE:600572)

Sep 30
It's A Story Of Risk Vs Reward With Zhejiang CONBA Pharmaceutical Co.,Ltd. (SHSE:600572)

Is Zhejiang CONBA PharmaceuticalLtd (SHSE:600572) Using Too Much Debt?

Sep 12
Is Zhejiang CONBA PharmaceuticalLtd (SHSE:600572) Using Too Much Debt?

Is Zhejiang CONBA Pharmaceutical Co.,Ltd. (SHSE:600572) Worth CN¥4.3 Based On Its Intrinsic Value?

Aug 20
Is Zhejiang CONBA Pharmaceutical Co.,Ltd. (SHSE:600572) Worth CN¥4.3 Based On Its Intrinsic Value?

Here's Why Zhejiang CONBA PharmaceuticalLtd (SHSE:600572) Can Manage Its Debt Responsibly

May 21
Here's Why Zhejiang CONBA PharmaceuticalLtd (SHSE:600572) Can Manage Its Debt Responsibly

Financial Position Analysis

Short Term Liabilities: 600572's short term assets (CN¥4.4B) exceed its short term liabilities (CN¥2.5B).

Long Term Liabilities: 600572's short term assets (CN¥4.4B) exceed its long term liabilities (CN¥536.0M).


Debt to Equity History and Analysis

Debt Level: 600572 has more cash than its total debt.

Reducing Debt: 600572's debt to equity ratio has reduced from 55.6% to 6.2% over the past 5 years.

Debt Coverage: 600572's debt is well covered by operating cash flow (166%).

Interest Coverage: 600572 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 14:37
End of Day Share Price 2024/12/25 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Zhejiang CONBA Pharmaceutical Co.,Ltd. is covered by 12 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Shuchang LiuChangjiang Securities Co. LTD.
Feifei XuChina Merchants Securities Co. Ltd.
Ling Bo TuChina Minzu Securities